Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Up 36.2% in October

Vivos Therapeutics, Inc. (NASDAQ:VVOS) saw a large growth in short interest in the month of October. As of October 31st, there was short interest totalling 95,100 shares, a growth of 36.2% from the October 15th total of 69,800 shares. Based on an average daily volume of 1,340,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 2.2% of the shares of the stock are sold short.

Vivos Therapeutics Stock Down 9.0 %

VVOS opened at $2.84 on Friday. The firm’s fifty day simple moving average is $2.79 and its two-hundred day simple moving average is $2.52. Vivos Therapeutics has a 52-week low of $1.91 and a 52-week high of $48.79. The company has a market cap of $13.53 million, a price-to-earnings ratio of -0.40 and a beta of 7.71.

Vivos Therapeutics (NASDAQ:VVOS) last posted its quarterly earnings data on Wednesday, August 14th. The company reported ($0.60) EPS for the quarter. The firm had revenue of $4.05 million for the quarter. Vivos Therapeutics had a negative return on equity of 652.32% and a negative net margin of 85.90%. On average, research analysts forecast that Vivos Therapeutics will post -3.13 EPS for the current year.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets increased their price target on Vivos Therapeutics from $6.40 to $6.60 and gave the stock a “buy” rating in a research report on Tuesday, August 20th.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.